Jennifer L Schutzman

4PUBLICATIONS
74CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (4)

|Oct 27, 2025
PI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with PIK3CA-Mutated Solid Tumors and in Preclinical Models.

Dejan Juric, Kyung Song, Radia M Johnson

|Jul 09, 2025
Single-Agent Divarasib in Patients With KRAS G12C-Positive Non-Small Cell Lung Cancer: Long-Term Follow-Up of a Phase I Study.

Adrian G Sacher, Wilson H Miller, Manish R Patel

|Sep 05, 2024
Phase I/Ib Trial of Inavolisib Plus Palbociclib and Endocrine Therapy for PIK3CA-Mutated, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced or Metastatic Breast Cancer.

Komal L Jhaveri, Melissa K Accordino, Philippe L Bedard

|Jul 12, 2024
Circulating Tumor DNA Dynamics Reveal KRAS G12C Mutation Heterogeneity and Response to Treatment with the KRAS G12C Inhibitor Divarasib in Solid Tumors.

Yoonha Choi, Neekesh V Dharia, Tomi Jun

Pageof 1

Frequent Collaborators

3 joint publications

Stephanie Royer-Joo

2 joint publications

Yoonha Choi

2 joint publications

Neekesh V Dharia

2 joint publications

Tomi Jun